At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years at informed consent
- ✓ECOG performance status 0-2 (if PS 2, must be related to anemia)
- ✓Part 1: MDS with IPSS-R very low, low, or intermediate risk
- ✓Part 1: <5% blasts in bone marrow
- ✕MDS with deletion of chromosome 5q (Del5q)
- ✕Secondary MDS from chemical injury or prior chemotherapy/radiation
- ✕Active infection requiring parenteral antibiotics within 28 days or oral antibiotics within 14 days
- ✕Uncontrolled heart disease or NYHA Class III/IV heart failure
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)
In Brief
A Phase 2 clinical trial evaluating Elritercept for Myelodysplastic Syndromes and Cytopenia. Currently recruiting, targeting 160 participants across 47 sites in 8 countries.
Detailed Summary
The main aim of this study is to learn how safe elritercept is and how well adults with anemia associated with lower-risk MDS tolerate treatment with different doses of elritercept. Other aims are to learn how safe elritercept is by looking at how many participants have MDS that worsens during the study and learn about the effects of elritercept on anemia linked to MDS. The study will also look to learn how elritercept affects the production of healthy RBCs.
Study Details
Timeline
Interventions
Elritercept SC injection.